DAX24.290 -0,3%ESt505.359 -0,3%Top 10 Crypto15,85 +1,4%Dow44.342 -0,3%Nas20.896 +0,1%Bitcoin101.709 +0,9%Euro1,1632 -0,1%Öl69,38 +0,2%Gold3.366 +0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Novo Nordisk A3EU6F DroneShield A2DMAA Clara Technologies A3E4MS ASML NV A1J4U4 Lufthansa 823212 Deutsche Telekom 555750 Tesla A1CX3T RENK RENK73 BYD A0M4W9 Allianz 840400 Amazon 906866 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen freundlich -- TRATON: Gunnar Kilian legt Aufsichtsratsmandat nieder -- Merck erhält bedingte EU-Zulassung für Ezmekly -- Northvolt im Fokus
Top News
Novo-Nordisk-Aktie im Fokus: Quartalszahlen und optimistische Analystenprognosen Novo-Nordisk-Aktie im Fokus: Quartalszahlen und optimistische Analystenprognosen
China droht EU vor Gipfel mit Vergeltung wegen Sanktionen China droht EU vor Gipfel mit Vergeltung wegen Sanktionen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Handeln
CSL Aktien-Sparplan
71,50 EUR -2,50 EUR -3,38 %
BMN
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
KGV36,04Div. Rendite1,24%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA115DF

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS12637N2045

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCSLLY

CSL Aktien News

DatumMeistgelesen
Dow JonesMÄRKTE ASIEN/Sehr feste Kurse in Tokio nach Feiertagspause
ZacksCarlyle Secured Lending (CGBD) Enters Merger Deal With CSL III
PR NewswireCSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
PR NewswireCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
Dow JonesEU sichert sich Millionen Dosen Vogelgrippe-Impfstoff
PR NewswireCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Dow JonesMÄRKTE ASIEN/Etwas leichter - Börsen mehrheitlich wegen Feiertagen geschlossen
Dow JonesMÄRKTE ASIEN/Etwas leichter - Börsen mehrheitlich wegen Feiertagen geschlossen
PR NewswireCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
PR NewswireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
PR NewswireHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
PR NewswireSwissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B
PR NewswireCSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
PR NewswireCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
PR NewswireCSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...
PR NewswireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.